Search Patents
  • Chimeric Compositions and Methods for Regulating Plant Gene Expresssion
    Publication number: 20110271396
    Abstract: The invention provides a method for producing a chimeric promoter polynucleotide capable of controlling transcription of an operably linked polynucleotide in a plant cell or plant, wherein the method comprises combining: a) at least one sequence motif comprising a sequence with at least 70% identity to SEQ ID NO:1, 11 or 12, and b) another polynucleotide sequence. The invention also provides chimeric promoters polynucleotides comprising the sequences defined in a) and b). The invention also provides constructs, vectors, host cells, plant cells and plants comprising the chimeric promoter polynucleotides of the invention. The invention also provided methods for modifying gene expression and phenotype of plant cells and plants by transforming the plant cells and plants with the chimeric promoter polynucleotides of the invention.
    Type: Application
    Filed: May 12, 2009
    Publication date: November 3, 2011
    Inventors: Richard Espley, Roger P. Hellens, Andrew C. Allan, David Chagne, Cyrill Brendolise
  • Compositions and methods for modulating pigment production in plants
    Patent number: 7973216
    Abstract: This invention relates to polynucleotides encoding novel transcription factors and to the encoded transcription factors, that are capable of regulating anthocyanin production in plants. The invention also relates to constructs and vectors comprising the polynucleotides, and to host cells, plant cells and plants transformed with the polynucleotides, constructs and vectors. The invention also relates to methods of producing plants with altered anthocyanin production and plants by the methods.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: July 5, 2011
    Assignee: The New Zealand Institute for Plant and food Research Limited
    Inventors: Richard Espley, Roger Hellens, Andrew C. Allan
  • Chimeric promoters comprising MYB10 repeat element and methods for regulating plant gene expression
    Patent number: 8686125
    Abstract: The invention provides a method for producing a chimeric promoter polynucleotide capable of controlling transcription of an operably linked polynucleotide in a plant cell or plant, wherein the method comprises combining: a) at least one sequence motif comprising a sequence with at least 70% identity to SEQ ID NO:1, 11 or 12, and b) another polynucleotide sequence. The invention also provides chimeric promoters polynucleotides comprising the sequences defined in a) and b). The invention also provides constructs, vectors, host cells, plant cells and plants comprising the chimeric promoter polynucleotides of the invention. The invention also provided methods for modifying gene expression and phenotype of plant cells and plants by transforming the plant cells and plants with the chimeric promoter polynucleotides of the invention.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: April 1, 2014
    Assignee: The New Zealand Institute for Plant and Food Research Limited
    Inventors: Richard Espley, Roger P. Hellens, Andrew C. Allan, David Chagne, Cyril Brendolise
  • Compositions and Methods for Modulating Pigment Production in Plants
    Publication number: 20110072539
    Abstract: This invention relates to polynucleotides encoding novel transcription factors and to the encoded transcription factors, that are capable of regulating anthocyanin production in plants. The invention also relates to constructs and vectors comprising the polynucleotides, and to host cells, plant cells and plants transformed with the polynucleotides, constructs and vectors. The invention also relates to methods of producing plants with altered anthocyanin production and plants by the methods.
    Type: Application
    Filed: August 30, 2006
    Publication date: March 24, 2011
    Inventors: Richard Espley, Roger Hellens, Andrew C. Allan
  • Pyrimidinone derivatives for the treatment of atherosclerosis
    Patent number: 6559155
    Abstract: Pyrimidones of formula (I) are inhibitors of the enzyme LpPLA2 and thereof use in treating inter alia atherosclerosis, in which: R1 is COOH or a salt thereof, COOR10, CONR11R12, CN or CH2OH; R2 is a mono- or bicyclic aromatic ring system or a mono- or bicyclic heteroaromatic ring system; R3 is C1-20alkyl, C3-6cycloalkyl, C3-6cycloalkylC1-5alkyl, C1-10alkoxyC1-10alkyl, or an aromatic or heteroaromatic ring system; W is SO2 or a bond; X is O or S; and Y is a group of the formula A1—A2—A3 in which A1 and A3 each represent a bond or a straight chain or branched alkylene group, said alkylene group(s) containing a total of 1 to 10 carbon atoms and A2 represents a bond or O, S, SO, SO2, CO, C═CH2, CONH, NHCO, CR15R16, CH═CH or C═C, providing that when A2 is O, S, SO, SO2 or CONH, A3 contains at least two carbon atoms linking the A2 group and the CH2 group in formula (I).
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: May 6, 2003
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Colin Andrew Leach, Stephen Allan Smith
  • Method and apparatus for producing low sulfur metallized pellets
    Patent number: 5340378
    Abstract: An improved method and apparatus for forming metallized iron by direct reduction of particulate iron oxide is disclosed. Spent reducing gas is recycled from the reduction furnace through a cooler-scrubber and a catalyst-containing stoichiometric gas reformer. Upon removing the process gas from the cooler-scrubber, it is contacted with a chlorine dioxide spray, then compressed and cooled, the sulfur compound removed, and the process gas recycled either into the furnace cooling zone, or directly into the reformer, or divided and directed into both uses. Thus, most of the sulfur containing components of the spent reducing gas are removed, thereby reducing the sulfur contamination of the gas reformer catalyst. Reducing sulfur contamination of the gas reformer catalyst improves the overall efficiency of the direct reduction process.
    Type: Grant
    Filed: May 28, 1993
    Date of Patent: August 23, 1994
    Assignee: Georgetown Steel Corporation
    Inventor: Allan C. Huestis
  • Porous PTFE structures
    Patent number: 5677031
    Abstract: A porous polytetrafluoroethylene (PTFE) structure particularly for use as a liquid filter comprises particles of granular-type PTFE fused together to form a porous integral network. The structure is formed by spraying an aqueous suspension of granular PTFE particles and baking at a temperature of 335.degree.-350.degree. C. Typically the specific gravity is 0.8 to 1.54. The crystallinity is less than 95%. The structure may be supported on a perforate substrate such as stainless steel mesh.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: October 14, 1997
    Assignee: W. L. Gore & Associates, Inc.
    Inventors: Andrew Miller Allan, Brian Andrew Barker
  • Quinazolinone derivatives useful as anti-hyperalgesic agents
    Publication number: 20060154942
    Abstract: The present invention relates to quinazolinones of formula (I) wherein R1 is hal; a); b); or c); X is N or CR8; R2 is hal; nitro; C1-C6alkylcarbonyl; C1-C6alkyl or C3-C6cycloalkyl; R3 is C1-C6alkyl; C1-C6alkoxy or amino; and wherein the further radicals have the meanings as defined in the specification, which compounds exhibit human vanilloid antagonistic activity; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 10, 2003
    Publication date: July 13, 2006
    Inventors: Andrew Culshaw, Edward Dziadulewicz, Allan Hallett, Terance Hart
  • METHODS AND COMPOSITIONS FOR PDGF-CC INHIBITION
    Publication number: 20220275075
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of platelet derived growth factor C (PDGF-C). Such antibodies may be used for the modulation of PDGF-C activity in or secreted from a cell to study its effects on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with PDGF-C signing pathway.
    Type: Application
    Filed: May 9, 2022
    Publication date: September 1, 2022
    Applicant: Paracrine Therapeutics AB
    Inventors: Ulf Eriksson, Hong Li, Andrew Scott, Laura Allan
  • Methods and compositions for PDGF-CC inhibition
    Patent number: 11352420
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of platelet derived growth factor C (PDGF-C). Such antibodies may be used for the modulation of PDGF-C activity in or secreted from a cell to study its effects on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with PDGF-C signing pathway.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: June 7, 2022
    Assignee: PARACRINE THERAPEUTICS AB
    Inventors: Ulf Eriksson, Hong Li, Andrew Scott, Laura Allan
  • METHODS AND COMPOSITIONS FOR PDGF-CC INHIBITION
    Publication number: 20210179701
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of platelet derived growth factor C (PDGF-C). Such antibodies may be used for the modulation of PDGF-C activity in or secreted from a cell to study its effects on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with PDGF-C signing pathway.
    Type: Application
    Filed: June 30, 2017
    Publication date: June 17, 2021
    Inventors: Ulf Eriksson, Hong Li, Andrew Scott, Laura Allan
  • METHOD FOR THE TREATMENT OF PAIN AND OSTEOARTHRITIS WITH C-FMS ANTAGONISTS
    Publication number: 20180237531
    Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.
    Type: Application
    Filed: April 17, 2018
    Publication date: August 23, 2018
    Inventors: Stefan STEIDL, John Allan HAMILTON, Andrew David COOK
  • Method for treatment of osteoarthritis with C-Fms antagonists
    Patent number: 10005840
    Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: June 26, 2018
    Assignees: MORPHOSYS AG, THE UNIVERSITY OF MELBOURNE
    Inventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
  • Use of c-Fms antagonists
    Publication number: 20140205608
    Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.
    Type: Application
    Filed: July 17, 2012
    Publication date: July 24, 2014
    Applicants: MorphoSys AG, The University of Melbourne
    Inventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
  • Use of M-CSF antibodies in the treatment of osteoarthritis or pain
    Patent number: 9243066
    Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: January 26, 2016
    Assignees: University of Melbourne, Morpho Sys AG
    Inventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
  • Use of c-Fms antagonists
    Publication number: 20160185867
    Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 30, 2016
    Inventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
  • Tool for applying clips
    Patent number: 6938453
    Abstract: A closure tool (10, 40) for closing heavy-duty clips (11) as used for example in the building trade and in agriculture has a body (13), a pair of handles (14) mounted on the body (13) on pivots (15) and a pair of anvils (18, 20) movable relative to each other from a spaced position to closure position in response to relative movement of the handles (14) and the body (13). A moving member (17) is engaged by the handles (14) and is movable therewith, and one of the anvils (18) is connected to and movable with the moving member (17). The handles (14) may have spigots (44) engaged in a slot (43) in a cylindrical moving member (17) in a barrel part (41) of the body (13), or each handle (14) may have a quadrant shaped first gear engaging a rack second gear moving member slidably mounted in the body.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: September 6, 2005
    Assignee: J. & H. Rosenheim Limited
    Inventors: Raymond Allan Pickup, Andrew King
  • QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS
    Publication number: 20080293939
    Abstract: The present invention relates to quinazolinones of formula (I) wherein R1 is hal; a); b); or c); X is N or CR8; R2 is hal; nitro; C1-C6alkylcarbonyl; C1-C6alkyl or C3-C6cycloalkyl; R3 is C1-C6alkyl; C1-C6alkoxy or amino; and wherein the further radicals have the meanings as defined in the specification, which compounds exhibit human vanilloid antagonistic activity; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: December 4, 2007
    Publication date: November 27, 2008
    Inventors: Andrew James Culshaw, Edward Karol Dziadulewicz, Allan Hallett, Terance William Hart
  • Iridoid-saccharide compound and method of using same
    Publication number: 20080032939
    Abstract: A method for treatment of hyperproliferative tissue which by exposing the hyperproliferative tissue to a sufficient quantity of a purified iridoid compound to inhibit its growth, where the iridoid compound includes a polysubstituted cyclopenta(c)dihydropyran where the cyclopenta ring is substituted at its 2? position with a ketofuryl group, where the numbering of the fused cyclopenta(c)dihydropyran ring structure includes heterocyclic oxygen, is counterclockwise and begins at the first carbon atom counterclockwise from the cyclopenta ring so that oxygen is in the 2 position in the pyran ring. The invention also includes the mouse iridoid compounds.
    Type: Application
    Filed: September 13, 2007
    Publication date: February 7, 2008
    Applicant: Health Research, Inc.
    Inventors: Ravindra Pandey, Mahabeer Dobhal, Andrew Graham, Allan Oseroff
  • Iridoid-saccharide compound and method of using same
    Publication number: 20050222053
    Abstract: A method for treatment of hyperproliferative tissue which by exposing the hyperproliferative tissue to a sufficient quantity of a purified iridoid compound to inhibit its growth, where the iridoid compound includes a polysubstituted cyclopenta(c)dihydropyran where the cyclopenta ring is substituted at its 2? position with a ketofuryl group, where the numbering of the fused cyclopenta(c)dihydropyran ring structure includes heterocyclic oxygen, is counterclockwise and begins at the first carbon atom counterclockwise from the cyclopenta ring so that oxygen is in the 2 position in the pyran ring. The invention also includes the mouse iridoid compounds.
    Type: Application
    Filed: October 28, 2004
    Publication date: October 6, 2005
    Applicant: Health Research, Inc.
    Inventors: Ravindra Pandey, Mahabeer Dobhal, Andrew Graham, Allan Oseroff
Narrow Results

Filter by US Classification